Barclays Maintains Overweight on Indivior Pharmaceuticals, Raises Price Target to $45
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsPrice Target
Barclays analyst Glen Santangelo maintains Indivior Pharmaceuticals (NASDAQ:INDV) with a Overweight and raises the price target from $43 to $45.
Barclays analyst Glen Santangelo maintains Indivior Pharmaceuticals (NASDAQ:INDV) with a Overweight and raises the price target from $43 to $45.